Loading...

MedXY News - cardiovascular outcomes

MedXY AI/MedXY News/Tag: cardiovascular outcomes

MedXY News

EnglishTag

cardiovascular outcomes

40 all articles · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial immunotherapy heart failure obesity atrial fibrillation cardiovascular risk Cardiology biomarkers clinical trials Hypertension oncology public health critical care artificial intelligence breast cancer Alzheimer's disease diabetes cardiovascular disease type 1 diabetes nutrition chronic kidney disease

Latest news

Tag

SGLT2 Inhibitors Remain Protective Even After Severe eGFR Decline: Pooled Trial Analysis Across Cardio‑Renal‑Metabolic Populations

SGLT2 Inhibitors Remain Protective Even After Severe eGFR Decline: Pooled Trial Analysis Across Cardio‑Renal‑Metabolic Populations

By MedXY|Nov 29, 2025

A pooled analysis of five randomized trials (n=26,946) found that severe eGFR deterioration (

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

Nov 11, 2025

In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in people with overweight/obesity without diabetes. Benefits were largely independent of baseline adiposity and weight loss; waist circumference redu

PCSK9 Inhibition Prevents First Major Cardiovascular Events: VESALIUS‑CV trial

PCSK9 Inhibition Prevents First Major Cardiovascular Events: VESALIUS‑CV trial

By MedXY|Nov 10, 2025

In the VESALIUS‑CV trial, evolocumab reduced first major adverse cardiovascular events by 25% (3‑point MACE) and 19% (4‑point MACE) versus placebo over 4.6 years in patients with atherosclerosis or diabetes and no prior MI or stroke.

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study

By MedXY|Nov 7, 2025

In a 241,981-patient emulated trial using modern causal methods, sustained GLP‑1RA use yielded the lowest 2.5‑year MACE risk, followed by SGLT2is, sulfonylureas, and DPP4is; the GLP‑1RA advantage over SGLT2is was greatest in older adults an

Low-Dose Colchicine in Acute Myocardial Infarction: Insights from an Updated Meta-Analysis

Low-Dose Colchicine in Acute Myocardial Infarction: Insights from an Updated Meta-Analysis

By MedXY|Oct 12, 2025

An updated meta-analysis evaluates the effects of 0.5 mg colchicine on clinical outcomes after acute myocardial infarction, showing reduced hospital readmission but increased diarrhea risk without significant impact on major cardiovascular

Balancing Risks and Benefits: Individual Data Analysis of Intensive vs. Standard Blood Pressure Control on Cardiovascular and Renal Outcomes

Balancing Risks and Benefits: Individual Data Analysis of Intensive vs. Standard Blood Pressure Control on Cardiovascular and Renal Outcomes

By MedXY|Oct 11, 2025

A large pooled analysis shows that intensive blood pressure control reduces cardiovascular events with a modest increase in adverse effects, resulting in an overall net clinical benefit.

β-Blockers in Post-Myocardial Infarction Patients with Mildly Reduced Ejection Fraction: A Meta-Analysis of Randomized Trials

β-Blockers in Post-Myocardial Infarction Patients with Mildly Reduced Ejection Fraction: A Meta-Analysis of Randomized Trials

By MedXY|Oct 11, 2025

This meta-analysis reveals that β-blocker therapy reduces mortality and adverse cardiovascular events in myocardial infarction patients with mildly reduced left ventricular ejection fraction (40–49%), extending benefits beyond reduced LVEF

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials

By MedXY|Oct 11, 2025

Pooled data from VICTORIA and VICTOR trials demonstrate that vericiguat significantly reduces cardiovascular death and heart failure hospitalization in a wide spectrum of patients with heart failure and reduced ejection fraction, including

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

By MedXY|Oct 11, 2025

The VICTOR trial evaluated vericiguat in HFrEF patients without recent worsening, showing no significant reduction in composite cardiovascular death or heart failure hospitalization, but fewer cardiovascular and all-cause deaths with accept

Exploring the Impact of Reduced Left Ventricular Function on Outcomes After PCI in Chronic Kidney Disease Patients

By MedXY|Oct 9, 2025

Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence

By MedXY|Oct 9, 2025

This review synthesizes evidence on high-dose versus standard-dose influenza vaccines for cardiovascular outcomes in older adults, focusing on the large DANFLU-2 trial and complementary studies, highlighting modest cardiovascular benefits a

DIALIZE-Outcomes Trial: Sodium Zirconium Cyclosilicate Effect on Cardiovascular Outcomes in Hemodialysis Patients with Hyperkalemia

DIALIZE-Outcomes Trial: Sodium Zirconium Cyclosilicate Effect on Cardiovascular Outcomes in Hemodialysis Patients with Hyperkalemia

By MedXY|Oct 9, 2025

The DIALIZE-Outcomes trial assessed sodium zirconium cyclosilicate (SZC) in controlling predialysis hyperkalemia among hemodialysis patients but found no reduction in arrhythmia-related cardiovascular events despite improved potassium contr

Multidomain Rehabilitation Reduces Cardiovascular Events in Older Adults Post-Myocardial Infarction: Insights from the PIpELINe Trial

Multidomain Rehabilitation Reduces Cardiovascular Events in Older Adults Post-Myocardial Infarction: Insights from the PIpELINe Trial

By MedXY|Oct 7, 2025

A multidomain rehabilitation program combining cardiovascular risk control, dietary counseling, and exercise significantly lowers the risk of cardiovascular death or unplanned hospitalization within one year in older myocardial infarction s

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial

Clinical Updates

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial

By MedXY|Oct 7, 2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence

Clinical Updates

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence

By MedXY|Oct 6, 2025

This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone’s efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing future dire

Spironolactone in Chronic Haemodialysis Patients: Insights from the ALCHEMIST Trial and Updated Meta-Analysis

Spironolactone in Chronic Haemodialysis Patients: Insights from the ALCHEMIST Trial and Updated Meta-Analysis

By MedXY|Oct 6, 2025

The ALCHEMIST trial reveals spironolactone does not improve cardiovascular outcomes in high-risk chronic haemodialysis patients, aligning with a meta-analysis that challenges the benefit of mineralocorticoid receptor antagonists in this pop

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial

By MedXY|Oct 5, 2025

The FOURIER trial reveals intensive LDL-C lowering with evolocumab substantially reduces cardiovascular events in type 1 diabetes patients with ASCVD, highlighting significant clinical benefit and urging further dedicated research.

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY|Oct 3, 2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY|Oct 3, 2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Evaluating the MISSION Act: Implications for Cardiovascular Procedure Outcomes in U.S. Veterans

Evaluating the MISSION Act: Implications for Cardiovascular Procedure Outcomes in U.S. Veterans

By MedXY|Oct 1, 2025

The MISSION Act reduced travel times to cardiac procedures for veterans distant from VA centers but was linked to higher short-term adverse cardiovascular events for PCI and CABG, highlighting complex trade-offs in access and care quality.

Ask MedXY AI

Most popular

Initiation, Adherence, and Persistence to Guideline-Directed Medical Therapy After Heart Failure Hospitalization: Bridging the Gap Between Prescription and Sustained Use

Family Medicine & Nutrition

How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk

SSRIs vs. Second-Generation Antipsychotics for Managing Agitation in Dementia: Real-World Evidence from Nursing Homes

Clinical Updates

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Olorofim for Poorly Controlled Disseminated Coccidioidomycosis: Phase 2b Clinical Efficacy and Safety Insights